Furthermore, tDCS treatment significantly decreased the levels of pro-inflammatory cytokines such as interleukin (IL)-1β (Regner et al., 2020), IL-6 (Zhang et al., 2020), and tumor necrosis factor (TNF)-α (Callai et al., 2022) and increased the levels of anti-inflammatory cytokines such as IL-10 (Zhang et al., 2020) in cerebral ischemic penumbra, which can inhibit the neuroinflammatory response in cerebral ischemic penumbra and produce neuroprotective effects in the early stage of stroke. The gene discussed is IL6; the disease is stroke disorder.